glp-1 pen SUSTAINABLE DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND Understanding GLP-1 medications
Description
K.BalajiS.SureshP
The presence of GLP-1R in MCs has been confirmed by multiple research groups, including our own 5,15,16 and ex vivo data have shown that MCs increase their action potential firing frequency after the addition of both GLP-1 and the GLP-1R agonist exendin-4 17
Tirzepatide does not increase lactic acidosis risk
Its expansion and/or activation can protect against diet-induced obesity
Spot red flags: vague safety claims, partnerships with big pharma that sour quick
